O3:
1. Tidied-up transcript
(Filler words, sponsor spots, repeated phrases and time-stamps removed; section headings added for clarity.)
Intro & Motivation
Simon Hill (nutrition-science M.Sc.) opens by asking cardiologist Dr Thomas Dayspring for his first reaction to Hill’s coronary CT angiogram; Dayspring says he “can’t say I was shocked.” Hill explains he has eaten a whole-food plant-based diet for 10 years, has “perfect” annual blood tests, but wanted to know his true arterial status given a powerful family history (father and grandfather suffered MIs in their 40s).
Background & Definitions
Hill reviews atherosclerosis (plaque in the artery wall) and why apolipoprotein-B (ApoB) is now preferred over LDL-C as a particle count.
Why he ordered imaging
Approaching 40—the age his father’s first MI struck—Hill underwent:
- Coronary CT angiography (CTA) to quantify soft (non-calcified) plaque.
- Coronary artery calcium (CAC) scoring to see calcified plaque.
Imaging results
-
CTA: 61 mm³ total soft plaque, described by Dr Matt Budoff as “minimal non-obstructive.”
- 46 mm³ in the left anterior descending (LAD), 6.8 mm³ in the RCA, 8.1 mm³ in the LCx; all other branches clear.
- Percent atheroma volume (PAV) = 1.8 %.
-
CAC: Agatston score = 4 (≈50th percentile for men age 39).
Blood tests (Function Health panel)
Glucose 87 mg/dL, HbA1c 5.3 %, insulin 4 µIU/mL, triglycerides 75 mg/dL, hs-CRP < 0.2 mg/L.
However, LDL-C rose from 77 → 103 mg/dL and ApoB from 69 → 89 mg/dL after adding two daily servings of coconut-based yoghurt during marathon training.
Expert commentary (Dr Dayspring & Dr Dan Soffer)
- Plaque likely accumulated mainly before age 30 when Hill’s LDL-C ran 120-130 mg/dL.
- To halt or even reverse plaque, most data suggest LDL-C < 60 mg/dL (ApoB < 55–60 mg/dL), and “lower for longer is better.” (AHA Journals)
- Dayspring would “make you hypo-β”—i.e., push ApoB toward ≈ 40 mg/dL using drugs if needed.
Lifetime-LDL exposure concept
Hill plots Ference’s 5 000 mg·year LDL burden threshold:
- 29 y × 125 mg/dL = 3 625
- +10 y × 80 mg/dL = 800
- ➔ 4 425 mg·years—approaching symptomatic zone.
Pharmacologic options discussed
Statins as foundation (largest outcome-trial base), with ezetimibe, bempedoic acid, PCSK9 mAbs or siRNA as add-ons for potency/tolerability.
Safety of very-low cholesterol
Dayspring reviews endogenous cholesterol synthesis: peripheral and brain cells do not rely on LDL delivery; thus, plasma LDL < 30 mg/dL is not harmful to membranes, hormones or cognition.
Decision point
Hill sees two paths:
- Re-scan in 9 months to measure progression unmedicated.
- Start lipid-lowering therapy now to “slam the brakes” and stabilise plaque.
He is leaning to immediate therapy but has not decided; radiation dose of a second CTA is a remaining concern (modern CTA ≈ 1–4 mSv vs background 2.4 mSv/y). (PMC)
Closing
Hill pledges follow-up episodes on imaging, medications, nutraceuticals, and reversal evidence, and invites viewer feedback.
2. Concise summary
-
Findings: Minimal soft plaque (61 mm³, PAV 1.8 %) and trace calcium (CAC 4) still place Hill at about the median for men his age despite a decade of “ideal” lifestyle.
-
Interpretation: Plaque probably accumulated before dietary change; current ApoB 89 mg/dL may still allow slow progression.
-
Goal: Experts recommend ApoB ≤ 55 mg/dL (ideally ≈ 40) to arrest/regress plaque.
-
Next steps debated: Wait 9 months for a second scan vs. begin drug therapy now.
-
Take-home for viewers: Normal labs do not exclude sub-clinical atherosclerosis; early lifetime LDL lowering (diet ± medication) gives compounding benefit; individualised imaging can refine risk management. (YouTube )
3. Critique
| Aspect |
Strengths |
Limitations / Caveats |
| Transparency |
Hill publicly shares raw imaging data and blood panels, rare among influencers; invites expert critique. |
Single baseline scan means no personal progression rate yet; conclusions about past vs. current plaque are inferential. |
| Use of evidence |
Correctly emphasises ApoB and lifetime exposure, in line with 2023 AHA/ACC guidance to target ApoB < 60 mg/dL in very-high risk. (AHA Journals) |
The 5 000 mg·year “cliff” is illustrative but not a rigid threshold; real risk curves are probabilistic and modulated by blood pressure, smoking, etc. |
| Expert selection |
Invites respected lipidologists (Dayspring, Soffer) and imaging authority (Budoff); discussion reflects mainstream preventive-cardiology consensus. |
All guests are lipid-centric; absent are dissenting voices on CAC utility or on dietary strategies beyond low-SFA plant-based. |
| Dietary analysis |
Admits coconut yoghurt raised his LDL—good illustration of saturated-fat sensitivity. |
Underplays variability: some individuals may see minimal LDL change with coconut; viewers could misinterpret as universally “bad.” |
| Medical advice framing |
Reiterates that decision is personal, encourages viewers to test and consult clinicians. |
Nevertheless, episodes double as promotion for Hill’s supplement affiliates (Imate, Momentous, Bragg). Potential COI is disclosed but the interleaved ads may blur lines between education and marketing. |
| Radiation risk portrayal |
Acknowledges follow-up CTA carries radiation and plans to investigate. Modern low-dose protocols ~2–4 mSv (≈1–2 years background) are indeed modest. (PMC) |
Could quantify cumulative lifetime cancer risk (~0.01 %) to give viewers context. |
| Comparison with ketogenic CTA study |
Notes keto group added ~31 mm³ plaque in 12 mo vs his 61 mm³ lifetime—useful but fair. |
Study populations and LDL levels differed; mentioning confidence intervals and small sample caveats would guard against over-interpretation. |
| Physiology section |
Dayspring’s explanation that LDL is a return-to-liver carrier, not essential delivery, is accurate and pedagogic. |
Segment risks oversimplifying: endocrine tissues can up-regulate LDL-R under stress; nuance lost for lay audience. |
| Overall balance |
Episode is an excellent case study of “lifetime risk” thinking and how lifestyle + meds are complementary (Medicine 3.0). |
Heavy episode length (56 min) with mid-roll ads may fatigue viewers; a shorter companion video or infographic would broaden reach. |
Bottom line: The video is a well-crafted, evidence-aligned n-of-1 exploration that models proactive cardiovascular prevention. Its main message—that blood tests alone are not enough and “lower ApoB earlier” pays dividends—is strongly supported by current guidelines. Viewers should, however, recognise the single-person context, the promotional segments, and the probabilistic (not deterministic) nature of risk when applying these insights to their own care.
